Related references
Note: Only part of the references are listed.Effects of interleukin-2 in immunostimulation and immunosuppression
Jonathan G. Pol et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim et al.
IMMUNE NETWORK (2020)
Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma
Laurene S. Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer
Lijun Mo et al.
VACCINE (2017)
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
Rodrigo Vazquez-Lombardi et al.
NATURE COMMUNICATIONS (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Geok Choo Sim et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
Tania Carmenate et al.
JOURNAL OF IMMUNOLOGY (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
IL-2 Family of Cytokines in T Regulatory Cell Development and Homeostasis
Thomas R. Malek et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
M Ahmadzadeh et al.
BLOOD (2006)
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
SD Gillies et al.
BLOOD (2005)
Share Paper
